癌症患者生命质量测定量表体系之胃癌量表QLICP-ST的研制

背景与目的:有关癌症患者生命质量测定量表体系共性模块(qualityof life instruments for cancer patients-general module, QLICP-GM)的研制已有报道.本研究在此基础上研制癌症患者生命质量测定量表体系之胃癌量表(quality0f life instruments for cancer patients-stomach cancer,QLICP-ST),并对其进行评价.方法:采用量表开发的程序化方法研制量表,并应用该呈表对86例胃癌患者进行生命质量测评.用内部一致性系数、相关分析、配对t检验和探索性因子分析等对呈表的信度、效度和反应度进行考评.结果:总量表重测相关系数为0.98,各领域的重测相关系数均大于0.90.各个领域的内部一致性系数a在0.65以上,总量表的内部一致性系数a为0.91.相关分析与探索性因子分析结果显示量表的结构效度较好.躯体功能领域、心理功能领域、共性症状与剐作用领域、特异模块以及总量表治疗前后的生命质量得分差异均有统计学意义(P<0.05).而且,这些领域的标准化反应均数(standardized response mean,SRM)均在0.30以上.结论:QLICP-ST有较好的信度、效度和反应度,可用于临床胃癌患者生命质量的测评.     

癌症患者生命质量测定量表体系之大肠癌量表QLICP-GR的研制

背景与目的:癌症患者生命质量测定量表体系(quality of life instruments for cancer patients,QLICP)共性模块的研制已有报道,本研究在此基础上将研制大肠癌患者生命质量测定量表(QLICP-colorectal cancer,QLICP-CR).方法:采用量表开发的程序化决策方式研制适合中国文化背景下使用的QLICP-CR,并通过110例大肠癌患者的生存质量测定对量表进行评价.采用统计描述、相关分析、配对t检验和聚类分析等进行统计学处理.结果:总量表及各个领域的重测相关系数均在0.78以上;各领域内部一致性信度的α值除社会功能及共性症状和副作用领域分别为0.66、0.63外,其余均在0.85以上;各条目与其领域的相关均大于与其它领域的相关,相关系数r值大多都在0.6以上;总量表、共性模块、特异模块、心理功能及共性症状和副作用领域得分均显示治疗前后差异有统计学意义.结论:QLICP-CR具有较好的信度、效度及反应度,可作为我国大肠癌患者生命质量的测评工具.     

不同TNM分期乳腺癌患者规范化治疗后生存期生命质量评价

目的 评价规范化治疗后不同TNM分期乳腺癌患者的生命质量,以及欧洲五维健康量表(EQ-5D)在中国乳腺癌患者生命质量测评中的应用价值.方法 采用国内乳腺癌患者生命质量测定调查量表(QLICP-BR)和EQ-5D中文版,分别测量于6个月前完成规范化治疗(内分泌治疗除外)的乳腺癌患者生命质量.采用x2检验、单因素方差分析、协方差分析等统计学方法分析影响乳腺癌患者生命质量的因素.以QLICP-BR量表中共性模块(QLICP-GM)的得分和QLICP-BR总分为标准,采用Pearson相关分析评价EQ-5D量表的应用价值.结果 2010年3-9月共收集符合纳入排除标准的女性乳腺癌患者178例,其中0期和Ⅰ期47例,Ⅱ期81例,Ⅲ期和Ⅳ期50例.控制年龄、文化程度、职业、出生地(城市和农村)、家庭月收入、医保支付情况后,0期和Ⅰ期患者调整QLICP-BR总分为(72.55±3.10)分,Ⅱ期患者为(64.09±2.69)分,Ⅲ期和Ⅳ期患者为(58.21 ±3.00)分,不同TNM分期患者调整QLICP-BR总分差异有统计学意义(P =0.002).0期和Ⅰ期患者的QLICP-BR总分和社会功能调整生命质量得分均高于Ⅱ期患者(均P＜0.05);0期和Ⅰ期患者的QLICP-BR总分、特异模块、心理功能、社会功能和躯体功能调整生命质量得分均高于Ⅲ期和Ⅳ期患者(均P ＜0.05).不同TNM分期乳腺癌患者EQ-5D效用得分与相应的QLICP-GM得分和QLICP-BR总分均呈正相关(均P＜0.05).结论 TNM分期早的患者生命质量较好,早诊早治可以提高乳腺癌患者的生命质量.EQ-5D量表对不同TNM分期患者生命质量的测定有良好的区分度,可用于中国女性乳腺癌患者生命质量的评价.     

大肠癌患者生命质量及其影响因素的研究

目的 分析和探讨大肠癌患者的生命质量及其影响因素，评估疾病和治疗给病人生活带来的影响。方法 采用癌症病人生活功能指数量表(FLIC)对302例现患大肠癌患者进行生命质量的流行病学调查，所得资料采用逐步回归分析方法进行分析。结果 反映生命质量的FLIC均值为58．9分，95％可信区间为40．8～77．0分。患者文化程度、临床分期、自觉症状至初诊间隔时间、活动受限天数及初诊医院级别、医疗技术满意度和就医方便程度满意度是影响大肠癌患者生命质量的主要因素。结论 加强对医务人员的业务培训和指导，提高大肠癌的诊疗水平，普及大肠癌的防护知识，使人群熟悉大肠癌的常见症状和诊断手段，减少诊治延误有利于改善大肠癌患者的生命质量。     

大肠癌患者生命质量测定量表QLQ-CR68中文版的研制与应用评价

[目的]研制并通过实际测定评价欧洲癌症研究与治疗组织EORTC的大肠癌患者生命质量测定量表QLQ-CR68中文版的应用效果。[方法]通过翻译、回译、预调查和文化调试等步骤研制相应的中文版,通过110例大肠癌患者进的生命质量测定对量表的信度、效度和反应度进行评价。[结果]相关分析与因子分析显示较好的结构效度;内部一致性除认知功能(0.49)、化疗副作用(0.44)和社会功能(0.67)较低外,其它领域均在0.70以上;重测信度除化疗副作用为0.60外,其余均在0.7以上,而且大部分在0.80以上;发现核心模块的躯体功能、角色功能、社会功能、总健康状况领域及特异模块的所有领域治疗前后得分差异均有统计学意义。[结论]QLQ-CR68中文版具有较好的信度、效度和反应度,可用于中国大肠癌患者的生命质量测定。     

癌症患者生命质量测定量表体系之大肠癌量表QLICP-CR的研制

背景与目的:癌症患者生命质量测定量表体系(quality of life instrumentsfor cancer patients,QLICP)共性模块的研制已有报道,本研究在此基础上将研制大肠癌患者生命质量测定量表(QLICP-colorectal cancer,QLICP-CR)。方法:采用量表开发的程序化决策方式研制适合中国文化背景下使用的QLICP-CR,并通过110例大肠癌患者的生存质量测定对量表进行评价。采用统计描述、相关分析、配对t检验和聚类分析等进行统计学处理。结果:总量表及各个领域的重测相关系数均在0.78以上;各领域内部一致性信度的α值除社会功能及共性症状和副作用领域分别为0.66、0.63外,其余均在0.85以上;各条目与其领域的相关均大于与其它领域的相关,相关系数r值大多都在0.6以上;总量表、共性模块、特异模块、心理功能及共性症状和副作用领域得分均显示治疗前后差异有统计学意义。结论:QLICP-CR具有较好的信度、效度及反应度,可作为我国大肠癌患者生命质量的测评工具。     

大肠癌中文版生命质量总分客观指标影响因素逐步回归分析

[目的]探讨大肠癌中文版生命质量量表总分客观指标影响因素。[方法]采用大肠癌中文版生命质量量表(QLICP)对97例大肠癌患者生命质量进行测评。[结果]经逐步回归分析,大肠癌中文版生命质量量表总分客观指标影响因素主要是总蛋白、血氯、文化程度、年龄、白细胞计数和红细胞计数。[结论]大肠癌中文版生命质量量表总分客观指标影响因素是多因素的。建议医务人员治疗病人时应随时注意总蛋白、白细胞和红细胞等客观指标的变化情况。     

胃癌患者反刍性沉思水平影响因素分析

摘 要：［目的］ 了解胃癌患者反刍性沉思现状,分析其影响因素。［方法］ 方便抽样法抽取128例胃癌患者,采用事件相关反刍性沉思问卷法进行横断面研究。［结果］ 胃癌患者反刍性沉思水平处于中等偏下,受文化程度、家庭月收入、家庭支持、癌症分期、治疗方式和病情自评的影响,其中文化程度、家庭月收入和治疗方式可解释侵入性反刍性沉思总变异的42.5%,家庭支持、癌症分期和病情自评可解释目的性反刍性沉思总变异的67.8%。［结论］ 临床工作中要关注文化程度低、家庭月收入低、家庭关系一般的胃癌患者,促进其目的性反刍性沉思,降低其侵入性反刍性沉思水平,以促进患者的身心康复。     

生存质量评价在乳腺癌治疗中的应用

生存质量(quality oflife,QOL)是一个多维的概念,包括生理、心理、社会的满意程度,以及疾病或治疗有关的症状.在肿瘤治疗领域中,QOL评价被广泛应用于·临床治疗决策、治疗效果评价、疾病严重程度评定、肿瘤药物效应评价等方面,成为肿瘤治疗研究终点之一.乳腺癌患者由于其发病率高、生存期长、病损部位特殊等原因,QOLL往往严重下降.本文综述了常用的乳腺癌患者QOL评价工具,如线性模拟自我评价量表、癌症患者生活功能指标、乳腺癌化疗问卷、癌症生存者生存质量量表、欧洲癌症研究与治疗组织生存质量量表、肿瘤治疗功能评价量表、国际乳腺癌协作组生存质量量表、癌症患者生存质量测定量表等,并分析影响乳腺癌患者QOL的主要因素,这将有助于乳腺癌患者的-临床治疗决策和QOL的提高.     

鼻咽癌患者治疗后质量调整生命年的研究

目的 计算鼻咽癌患者治疗后的质量调整生命年,探讨影响质量调整生命年的因素.方法 对复查的304例鼻咽癌患者采用华盛顿大学生命质量量表简体中文第4版进行调查,以生命量表得分为权重,计算质量调整生命年.运用相关分析、t检验和多元线性回归评价QALY的影响因素.结果 平均权重是0.70.偏相关分析说明随访时间与QALY呈负相关,与生命质量无相关关系.结合QALY的单因素和多因素分析,提示:生命质量得分越高、N分期越早,QALY越高,而年龄、是否复发、随访时间与之呈负相关.结论 QALY结合考虑生命质量和生存时间的损失对鼻咽癌患者的影响,是综合评价患者疾病负担的有效方法.     

Independent psychometric validation of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire‐Endometrial Cancer Module (EORTC QLQ‐EN24)

The endometrial cancer (EC)‐specific Quality of Life module of the European Organization for Research and Treatment of Cancer (EORTC QLQ‐EN24), was developed and validated in one study. We independently validated and assessed the psychometric properties of the instrument. Two hundred and eight women with EC before surgery, during adjuvant treatment and follow‐up; in three different cancer centres completed the EORTC QLQ‐C30 and the EN24. The questionnaire's completion rate was 100%, except sexuality items, that were answered by 35% of patients. All item‐scale correlations for the multi‐item scales exceeded the .4 criterion and correlated well with their own scale, while correlations with the other scales were low. The internal consistency of all multi‐item scales were satisfactory (Cronbach's alpha coefficients ranging from .77 to .97). Discriminance for single‐item scales was low. The QLQ‐EN24 module discriminated well between clinically different patients, and there were no differences in quality of life questionnaire scales between patients with body mass index ≤30 when compared to those with >30. This validation study supports the reliability, as well as convergent and divergent validity of the EORTC QLQ‐EN24. The module is a useful instrument for the assessment of QOL in patients with EC. However, data concerning sexuality should be interpreted with caution.     

有氧运动对结直肠癌术后辅助化疗患者癌因性疲乏及生活质量的影响

目的:研究有氧运动对结直肠癌术后辅助化疗患者癌因性疲乏及生活质量的影响。方法:对60例结直肠癌术后行第一周期辅助化疗患者,按入院时住院号的奇偶数分为实验组与对照组,每组30例,实验组在接受常规出院健康的指导基础上进行有氧运动干预,对照组仅接受常规的出院康复指导。干预前、后采用Piper疲乏修正量表（revised piper fatigue scale,RPFS）、欧洲癌症治疗与研究组织的生活质量问卷（EORTC-QLQ-C30）对患者的CRF及生活质量进行评定分析。结果:有氧运动干预结束时,收集60例患者资料,结直肠癌患者术后辅助化疗,均有不同程度的癌因性疲乏（cancer-related fatigue,CRF）;两组RPFS评分比较,差异具有统计学意义（P＜0.05）;两组生活质量比较,有氧运动干预后EORTC-QLQ-C30分值明显提高,差异具有统计学意义（P＜0.05）。结论:结直肠癌术后辅助化疗患者普遍存在CRF;对该类患者采用有氧干预,能有效缓解其CRF的程度,并提高生活质量。     

Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial.

PURPOSE: This analysis of data from a randomized trial of chemotherapy in epithelial ovarian cancer sought to determine whether a relationship exists between the presence and severity of the most commonly observed toxic effects and the corresponding quality of life (QOL) items. PATIENTS AND METHODS: One hundred fifty-two eligible patients accrued from Canada by the National Cancer Institute of Canada Clinical Trials Group on a randomized trial of paclitaxel and cisplatin versus cyclophosphamide/cisplatin were included in the analysis. Toxicity to the chemotherapeutic treatments was subjectively evaluated using a trial-specific checklist for ovarian cancer and the European Organization for Research and Treatment of Cancer QLQ C30+3 questionnaire. Assessments were conducted at baseline, before each cycle of treatment (3 weeks), and at each 3-month follow-up during the next 2 years (or until progression). RESULTS: The most frequently observed symptoms experienced during or shortly following chemotherapy were neurosensory loss, lethargy, nausea, vomiting, and alopecia. Regression analyses revealed that change scores of QOL items related to motor weakness and gastrointestinal pain were common predictors for the change global QOL score during protocol treatment; and change scores of QOL items related to lethargy or fatigue and change toxicity grade of mood predicted the change global QOL score after patients were off treatment. CONCLUSION: The use of the European Organization for Research and Treatment of Cancer QLQ C30+3 and trial-specific checklist was able to assess the effect of expected toxicities on patient' s QOL during and following treatment, and so may be useful in addressing the concerns regarding methodological issues that have limited the acquisition of prospective, longitudinal treatment-related toxicity data.     

Cultural Adaptation and Validation of the Moroccan Version of the EORTC QLQ-CR29 in Patients with Colorectal Cancer

The increasing incidence of colorectal cancer in Morocco has generated a need for a disease-specific quality-of-life measuring instrument. The present study aims to translate and evaluate the reliability and validity of the Moroccan Arabic version of the EORTC QLQ-C29 measure in Moroccan subjects with colorectal cancer (CRC). Methods: Following translation to Moroccan Arabic, The QLQ-C30 and QLQ-C29 were administered to 135 patients treated for colorectal cancer (CRC) at the national oncology institute of Rabat, in the period from February 2016 to June 2018. Statistical analysis included reliability, convergent, and discriminant validity as well as known-groups comparisons. Results: (89 %) patients completed the questionnaires of the EORTC QLQ C-29 and EORTC QLQ C-30. The test –retest, administered to 25 patients and the ICCs for each item ranged from 0.61 to 0.93 indicating good to excellent reproducibility. The internal consistency coefficients for body image, urinary frequency, stool frequency scales were acceptable (Cronbach’s alpha ≥ 0.70), while the blood and mucus in the stool dimensions had lower reliability (0.65).  Multi-trait scaling analysis showed that multi-item scales met standards of convergent and discriminate validity. All Correlations between the EORTC QLQ C-29 and EORTC QLQ C-30 scores were low (r < 40). The known- group comparisons showed differences between group of patients based on tumor location and with/ without a stoma. Conclusion: The Moroccan Arabic Dialectal version of the QLQ-C 29 is a valid and reliable measure of health related quality of life (HRQOL) in patients with colorectal cancer.     

Validity of the Greek EORTC QLQ‐C30 and QLQ‐BR23 for measuring health‐related quality of life in breast cancer patients

KONTODIMOPOULOS N., NTINOULIS K. & NIAKAS D. (2011) European Journal of Cancer Care 20 , 354–361
Validity of the Greek EORTC QLQ‐C30 and QLQ‐BR23 for measuring health‐related quality of life in breast cancer patients The aim of this study was to assess construct validity and internal consistency reliability of the Greek EORTC QLQ‐C30 and QLQ‐BR23 instruments. A sample of female breast cancer patients (n= 105) were self‐administered the QLQ‐C30, QLQ‐BR23 and SF‐36 and questions on treatment and socio‐demographic status. Hypothesised scale structure, reliability (Cronbach's α) and construct validity (convergent, discriminative, concurrent and known‐groups) were assessed. Multitrait scaling confirmed scale structure of the QLQ‐C30 and QLQ‐BR23 with good item convergence (92% and 85%), and discrimination (87% and 84%) rates. Cronbach's α was >0.70 for all but one scale (cognitive functioning). Strength of Spearman's correlations between the QLQ‐C30 and SF‐36 scales assessing similar health‐related quality of life dimensions ranged from 0.25 to 0.64 (P < 0.01). Construct validity was confirmed with satisfactory results for interscale correlations and known‐groups comparisons. QLQ‐BR23 scales showed comparatively low (<0.40) correlations with QLQ‐C30 functional scales, and higher correlations with conceptually related symptom scales. Most QLQ‐C30 and QLQ‐BR23 scales discriminated between pre‐treatment and current treatment patients. The overall psychometric results for the Greek version of the QLQ‐C30 and QLQ‐BR23 confirmed it as a reliable and valid questionnaire for assessing breast cancer‐specific HRQoL in Greece.     

Is it useful to calculate sum scores of the quality of life questionnaire EORTC QLQ‐C30?

HINZ A., EINENKEL J., BRIEST S., STOLZENBURG J.‐U., PAPSDORF K. & SINGER S. (2012) European Journal of Cancer Care 21 , 677–683 Is it useful to calculate sum scores of the quality of life questionnaire EORTC QLQ‐C30? The aim of this paper is to test the psychometric properties of sum scores of the quality of life questionnaire EORTC QLQ‐C30. A sample of cancer patients (n= 1529) and a sample of the general population (n= 1185) were tested with the EORTC QLQ‐C30, the Hospital Anxiety and Depression Scale and the Multidimensional Fatigue Inventory. Three sum scores of the EORTC QLQ‐C30 are defined: a score concerning functioning, a score concerning symptoms and a total score. Compared with the two‐item quality of life scale of the EORTC QLQ‐C30, the psychometric quality of the total score and the functioning score is superior with respect to reliability, convergent validity and discriminant validity. Cronbach's alpha of the total score is 0.94 (cancer patients) and 0.95 (general population). The effect size discriminating between patients and controls is d= 0.83 for the total score, compared to only 0.50 obtained with the two‐item quality of life scale. The results prove that the calculation of sum scores provides useful information for clinicians who are interested in one generalising score of quality of life.     

Validation of the Chinese version of EORTC QLQ‐BN20 for patients with brain cancer

This is a single centre study in mainland China aiming to evaluate the reliability, validity and responsiveness of the Chinese version of EORTC QLQ‐BN20, designed by The European Organization for Research and Treatment of Cancer Quality of Life Group to evaluate the life quality of patients with brain tumour, cancer or metastases. One hundred and eighty‐eight patients with primary or secondary brain cancer from Hunan Provincial Tumor Hospital during September 2013 to June 2014 completed the Chinese EORTC QLQ‐C30/BN20 questionnaires developed by translation, back translation and cultural adaptation. Results were statistically analysed using SPSS17.0. The internal consistency (Cronbach's α coefficient) was between .753 and .869, the correlation coefficients among items and its own dimension were bigger than .4, and all items had a better correlation with its own dimension. The Spearman was used to analyse the correlation of each dimension between EORTC QLQ‐BN20 and EORTC QLQ‐C30, and the result showed that individual dimensions were moderately correlated, other dimensions were weakly correlated. In conclusion, the Chinese version of EORTC QLQ BN20 questionnaire had great relevance, reliability, convergent validity and discriminant validity. It provides a valuable tool for the assessment of health‐related quality of life in clinical studies of Chinese patients with primary or secondary brain cancer.     

Clinical validation of the EORTC QLQ-OG25 questionnaire for the evaluation of health-related quality of life in Mexican patients with esophagogastric cancers

Background: Quality of life questionnaires (QLQ) QLQ‐STO22 and QLQ‐OES18 are currently available to measure Health‐related quality of life (HRQL) in patients with Esophageal (EC) or Gastric cancer (GC). The QLQ‐OG25 integrates questions from both questionnaires to be useful for EC, Esophagogastric junction carcinoma (EGJC), and GC. Our aim was to validate the Mexican‐Spanish version. Patients and Methods: The translation procedure followed European Organization for Research and Treatment of Cancer (EORTC) guidelines. QLQ‐C30 and QLQ‐OG25 instruments were completed by patients with EC, EGJC, and GC. Patients were divided into three groups: (1) palliative treatment; (2) treatment with curative intent, and (3) survivors. Reliability and validity tests were performed. Results: One‐hundred sixty‐three patients were included: 62 women and 101 men (mean age, 54.9 years; range, 22–82 years). Sixty‐nine, seventy‐three, and twenty‐one patients were allocated into groups 1, 2, and 3, respectively. Questionnaire compliance rates were high and were well accepted. Group 3 patients reported better functional HRQL scores and lower symptom scores than patients in groups 2 and 1. Scales in the QLQ‐C30 and QLQ‐OG25 distinguished among other clinically distinct groups of patients. Cronbach's α coefficients of all multi‐item scales of the QLQ‐OG25 instrument were >0.7 (range, 0.7–0.83). Multitrait scaling analysis demonstrated good convergent and discriminant validity, even adjusting by location. Test–retest scores were consistent. Conclusion: The Mexican‐Spanish version of the EORTC QLQ‐OG25 questionnaire is reliable and valid for HRQL measurement in patients with esophagogastric cancer and can be used in clinical trials in the Mexican community. Copyright © 2011 John Wiley & Sons, Ltd.     

Comparison of early quality of life in patients treated with radiotherapy following mastectomy or breast conservation therapy: A prospective study

Introduction

To compare quality of life (QOL) in breast cancer patients from a developing country after breast conservation surgery (BCS) or mastectomy and adjuvant radiotherapy (RT).

Materials and methods

In a 6-month period, all consecutive early and locally advanced breast cancer patients treated with either BCS or mastectomy and treated with RT were analyzed. All patients who underwent mastectomy were treated with 45 Gray/20#/4 weeks. Patients with BCS were treated with a dose of 45-50 Gray/25#/5 weeks to whole breast followed by tumor bed boost (15 Gray/6#/6 days with suitable energy electrons). Prospective evaluation of QOL using EORTC QLQ C30 and breast cancer specific QLQ BR23 was done before starting RT (baseline), at mid-RT and at RT conclusion for all patients.

Results

One hundred and thirteen patients had mastectomy and 142 patients underwent BCS. Reliability test (Cronbach alpha) for questionnaire filling was 0.669-0.886. At pre-RT assessment, global QOL scores in mastectomy and BCS groups were 71.1 and 71.3, respectively. There was no significant difference in pre-RT EORTC QLQ C30 functional and symptom domains between mastectomy and BCS patients. However, social function domain score was higher in patients who underwent mastectomy (83 versus 73.9; p = 0.018). In QLQ BR23 domains, body image and sexual functioning domains were similar between the two groups. However, sexual enjoyment (10.9 versus 47.6; p = 0.006) and future perspective (7.4 versus 37.1; p = 0.036) domains were significantly better in BCS arm. There was no difference between systemic side effect (BRSSE), breast symptom (BRBS) and arm symptom (BRAS) domain scores between the groups. There was no significant difference in change of QOL scores between mastectomy and BCS patients at RT completion as compared to baseline.

Conclusions

There was no significant difference in quality of life in patients with BCS versus those with mastectomy. However, patients who underwent BCS had better sexual enjoyment and future perspective scores compared with mastectomy patients. There was no significant change of QOL domain scores after RT in mastectomy and BCS patients.     

Validation of the Polish version of the EORTC QLQ‐CX24 module for the assessment of health‐related quality of life in women with cervical cancer

The aim of our study was to undertake a prospective validation study of the Polish version of the EORTC cervical cancer (EORTC QLQ‐CX24) module used alongside the EORTC core measure. The translated module was pilot‐tested according to the established EORTC guidelines. Patients with histological confirmation of cervical cancer were eligible for the study. All patients filled out the Polish version of the EORTC QLQ‐CX24 module in addition to EORTC QLQ‐C30 and a demographic questionnaire. Standardised validity and reliability analyses were performed. One hundred and seventy‐one patients were enrolled into the study, mean age ± SD: 52.1 ± 9.6. Cronbach alpha coefficients, range 0.81–0.88, showed positive internal consistency. Re‐test was undertaken with 40 patients (23.4%). Interclass correlations for the EORTC QLQ‐CX24 ranged from 0.85 to 0.89 and proved appropriate test–retest reliability. Satisfactory convergent and discriminant validity in multi‐trait scaling analyses was seen. Concluding, the Polish version of the EORTC QLQ‐CX24 module is a reliable and valid tool for measuring HRQoL in patients with cervical cancer. It can be fully recommended for use in clinical and epidemiological settings in the Polish population.